Human papillomavirus (HPV) has been implicated as the main cause of cervical cancers in women and a frequent cause of anal, oropharyngeal, and vulvovaginal cancers in men and women. The primary focus of HPV management is prevention through vaccination. Because HPV is not just an infection of young people and the risk of HPV infection never goes away, mid-adult men and women can benefit from vaccination as well. This case-based activity addresses recent advances in vaccination options, challenges to increasing vaccination rates, and strategies for increasing vaccine uptake.
Case study with interactive benchmarking
After completing this activity, participants should be better able to:
- Assess 9-valent HPV vaccine status and eligibility in adult patients aged 27 through 45 who are not adequately vaccinated based on shared clinical decision making
- Discuss the risks of chronic HPV infection and the benefits of vaccination with patients and parents
- Integrate recommended, multidisciplinary strategies for improving HPV vaccination rates in eligible adult patients
NPs and PAs
Joint Accreditation Statement
In support of improving patient care, Continuing Education Alliance is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
Nursing contact hours: 0.50, which includes 0.50 hours of pharmacology credit
Nurse planner: Melanie Deal, NP
AAPA Credit Designation
Continuing Education Alliance has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until September 16, 2020. PAs should only claim credit commensurate with the extent of their participation.
PA Planner: Lawrence Herman, PA-C, MPA
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credits for learning and change.
This activity is supported by an educational grant from Merck.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Continuing Education Alliance, Practicing Clinicians Exchange, or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Continuing Education Alliance are required to disclose to the audience any relevant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Mahoney: consultant: GSK; grant/research support: Pfizer; speaker: Merck, Pfizer.
Mr Herman: consultant/speaker: Novo Nordisk.
None of the members of the Planning Committee or CE Alliance staff have any relevant relationships to disclose, except Mr Herman as noted above.
Participants wishing to earn CE/CME credit must:
- Read the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form online
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 67%.
The estimated time to complete this activity is 0.50 hours.
Release date: September 16, 2019
Expiration date: September 16, 2020
© 2020 Practicing Clinicians Exchange. All Rights Reserved. 96619MPCE